Click2Houston13h
Doctors at NexGenEsis Healthcare say they are revolutionizing pain relief with regenerative medicine
Dr. Abhishek Reddy and Dr. Joe Fuhrman stop by Houston Life to discuss their innovative approach to pain management.
Investing23h
FDA approves Vertex's first-in-class non-opioid analgesic for acute pain
Journavx works by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, which intercepts pain signals before they reach the brain. This approval marks the ...
RBC says Journavx review documents hint at focus in future chronic pain data
RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...
BioSpace2d
Vertex’s Journavx Changes the Pain Treatment Landscape But Opioids Here to Stay
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
WRIC2d
FDA approves first opioid-free painkiller in over two decades
The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...
Vertex Pharmaceuticals Incorporated (VRTX): Among Renaissance Technologies Portfolio’s Top Stock Picks
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
Facebook | The Stute5d
FDA approves first-of-its-kind non-opioid pain medication
On January 30, 2025, the US FDA approved Journavx (suzetrigine) 50mg oral tablets to use in the treatment of moderate to severe acute pain, making it the first non-opioid analgesic of its class to ...
JD Supra5d
FDA Approved Journavx, a Non-Opioid Drug for Pain Management
On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...